ClinicalTrials.gg
RecruitingNCT05898893Updated Jun 12, 2023

PARAT PLUS (The Tubridge Plus For The Treatment Of Wide-Necked Intracranial Aneurysms)

An interventional study of Microport NeuroTech Tubridge Plus flow-diverter Stent in Intracranial Aneurysm, sponsored by MicroPort NeuroTech Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-12.

Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.

Planned enrollment
37th of 49
99 · median 188
Started
2023
with 19 others
No phase
37 of 100
13 open now
Primary completion
2024-03
later than 4 of 41 live
Registered
58th of 100
by date
Lead sponsor
8 of 100
MicroPort NeuroTech Co., Ltd.

Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 37th largest by planned enrollment of the 49 interventional ones that give a count, is one of 20 that started in 2023, is one of 37 with no phase, reaches primary completion later than 4 of the 41 other live ones, and was the 58th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Intracranial Aneurysm with a site in China, or all of them as a file.
02

Study summary

A trial to evaluate the safety and efficacy of the Tubridge Plus flow-diverter stent for the treatment of intracranial wide-necked aneurysms.

03

Conditions studied

  • Intracranial Aneurysm

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years old (as of the date of signing the form);
  2. CTA, MRA or DSA angiography diagnosed as a large intracranial carotid artery or vertebral artery aneurysm (largest diameter of the aneurysm >= 10mm) or medium to small aneurysms (maximum diameter \<10mm) (including saccular aneurysms and recurrent saccular aneurysms);
  3. The neck of aneurysm 4mm or the body-to-neck ratio of aneurysm \< 2;
  4. The diameter of the parent vessel is 2.0mm-6.5mm;
  5. Subjects who are suitable for treatment with Tubridge Plus flow-diverted dense mesh stent alone or in combination with coils;
  6. Subjects are willing to follow up and evaluate according to the requirements of the clinical trial protocol;
  7. The subjects or their guardians can understand the purpose of the trial, participate voluntarily and sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Aneurysm related to AVM and MMD;
  2. Ruptured aneurysm within 30 days;
  3. Multiple aneurysms;
  4. Subjects with significant stenosis (stenosis rate >= 50%) or occlusion of parent artery
  5. Recurrent aneurysms after stent or stent-assisted coil embolization;
  6. Subjects with morphologies or lesions that may interfere with device use, including but not limited to: carotid artery dissection, vasculitis, Aortic dissection, restriction of vascular access (such as severe intracranial vascular tortuosity, severe intracranial vasospasm and no response to drug therapy, obstruction of device access due to other anatomical or clinical lesions);
  7. Subjects who are not suitable for anesthesia or endovascular treatment, such as severe diseases of the heart, lung, liver, spleen, and kidney, brain tumors, severe active infection, disseminated intravascular coagulation, and a history of severe mental illness;
  8. Subjects who underwent or plan undergo to major surgical operations (such as implantation of internal fixation devices for extremity fractures, tumor resection, major organ surgery, etc.) within 30 days before signing the form or 60 days after signing the informed consent form;
  9. Modified Rankin score >= 4 points ;
  10. The of the subjects is less than 12 months;
  11. Subjects who have participated in clinical trials of other drugs or medical devices before enrollment and did not reach the end point.
  12. The researchers judged that the subjects had poor compliance and could not complete the study as required;
  13. Subjects with suspected history of allergy to nickel-titanium, platinum, platinum-iridium alloys and other materials;
  14. Subjects who cannot receive antiplatelet aggregation or anticoagulation therapy;
  15. Subjects have or may have had a serious reaction to the contrast agent and could not complete the pre-treatment medication;
  16. Women who are pregnant or breastfeeding;
  17. Other conditions deemed inappropriate by the investigator to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Device: Microport NeuroTech Tubridge Plus flow-diverter Stent

Interventions

  • DeviceMicroport NeuroTech Tubridge Plus flow-diverter Stent

    Intracranial stent for wide-necked aneurysms

06

What researchers measure

Primary outcomes

  1. Complete occlusion(Raymond I) rate of aneurysm at 6 months after procedures

    Complete occlusion(Raymond I) rate of aneurysm at 6 months after procedures

    Time frame: 6months±30 days

Secondary outcomes

  1. Complete occlusion(Raymond I) rate of aneurysm at 12 months after procedures

    Complete occlusion(Raymond I) rate of aneurysm at 12 months after procedures

    Time frame: 12months±60 days

  2. Successful treatment(Raymond I or II)rate of aneurysm at 6 months after procedures

    uccessful treatment(Raymond I or II)rate of aneurysm at 6 months after procedures

    Time frame: 6months±30 days

  3. Successful treatment(Raymond I or II)rate of aneurysm at 12 months after procedures

    Successful treatment(Raymond I or II)rate of aneurysm at 12 months after procedures

    Time frame: 12months±60 days

  4. Retreatment rate of target aneurysm during follow-up

    Retreatment rate of target aneurysm during follow-up

    Time frame: 12months±60 days

  5. Success rate of stent implantation

    Success rate of stent implantation

    Time frame: Immediate evaluation after intervention

  6. The proportion of subjects with ipsilateral stroke or neurogenic death to their target aneurysm at 1 month postoperatively, 6 months postoperatively, and 1 year postoperatively;

    The proportion of subjects with ipsilateral stroke or neurogenic death to their target aneurysm at 1 month postoperatively, 6 months postoperatively, and 1 year postoperatively;

    Time frame: 12months±60 days

  7. The proportion of subjects with in-stent stenosis (stenosis ≥50% and <100%) within 6 months after procedures

    The proportion of subjects with in-stent stenosis (stenosis ≥50% and \<100%) within 6 months after procedures

    Time frame: 6months±30 days

  8. Proportion of subjects with complete in-stent occlusion within 6 months after procedures

    Proportion of subjects with complete in-stent occlusion within 6 months after procedures

    Time frame: 6months±30 days

  9. Device-related adverse events, serious adverse events within 1 month, 6 months, and 1 year after procedures

    Device-related adverse events, serious adverse events within 1 month, 6 months, and 1 year after procedures

    Time frame: 12months±60 days

07

Study locations

3 of 8 sites recruiting
  • West China Hospital of Sichuan University
    Chendu, China
    Not yet recruiting
    • Xiaodong Xie · Contact
  • Huashan Hospital of Fudan University
    Shanghai, China
    Recruiting
    • Yuxiang Gu · Contact
  • Shanghai Changhai Hospital
    Shanghai, China
    Not yet recruiting
    • Jianming Liu · Contact
  • Clinical Research Ethics Committee of Shenzhen Second People's Hospital
    Shenzhen, China
    Not yet recruiting
    • Jianming Wu · Contact
  • Zhongnan Hospital, Wuhan University
    Wuhan, China
    Not yet recruiting
    • Jingcao Chen · Contact
  • The Second Affiliated Hospital of PLA Air Force Military Medical University
    Xi'an, China
    Recruiting
    • Zhenwei Zhao · Contact
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
    Not yet recruiting
    • Sheng Guan · Contact
  • Zhujiang Hospital,Southern Medical University
    Zhujiang, China
    Recruiting
    • Chuanzhi Duan · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2024, 10 months after the start.

Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 10 months is below that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
Jun 12, 2023
StartActual
May 16, 2023
Primary completionEst.
Mar 2024
CompletionEst.
Dec 2024
Last update
Jun 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05898893
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
May 16, 2023
Primary completion
Mar 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jun 12, 2023

Study contacts

Huina Lu
Contact
HuiNa.Lu@microport.com
15901703529
Jianmin Liu
principal investigator · Changhai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion